Work

BNC105P is a vascular disruption agent that exhibits dual mode of action in a number of cancer indications and works additively in combination with bevacizumab.

Year: 2008

Type: article

Source: Cancer Research

Authors: Gabriel Kremmidiotis, Tina C. Lavranos, Donna Beaumont, Annabell F. Leske, Julian Adams, Michael O’Callaghan, Allison Hall, Deanna Bueti, Jelena Gasic, Bernard L. Flynn

Institution: Bionomics (Australia)

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3047373571

FWCI: 0.137

Cites:

Cited by: 1

Related to: 10